RxDoctor Payments DataLook up a doctor →

Mark Dirnberger

Neuromusculoskeletal Medicine & OMM · Mansfield, TXNPI 1841366465

Payments from drug & device makers

$8,066in general payments, 2019–2025

Across 399 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Scilex Pharmaceuticals Inc.$892
  • Amgen$605
  • Collegium Pharmaceutical, Inc.$564
  • AbbVie$452
  • plus $3K from 49 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neuromusculoskeletal medicine & omm providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$126,114
Medicare patients
162
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromusculoskeletal medicine & omm in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →